PTPN11 and cancer: At the pan-cancer level, various mutations, including those in FLG, CUBN, and PPFIA2, significantly increased Y62 phosphorylation of PTPN11; however, none of these mutations elevated Y62 phosphorylation of PTPN11 to an outlier level (Fig. 3E, right).